CTXR

Citius Pharmaceuticals, Inc. CTXR

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.49M

Quarter to Jun 30

Net income

$-11.92M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$823.0K total
GEODE CAPITAL MANAGEMENT, LLC
$130.3K-12.4%
VANGUARD CAPITAL MANAGEMENT LLC
$119.4K+17.7%
Miller Financial Services LLC
$78.6K+828.6%
CITADEL ADVISORS LLC
$75.5KNew
JANE STREET GROUP, LLC
$74.3K+445.4%
VANGUARD FIDUCIARY TRUST CO
$47.0K0.0%
BlackRock, Inc.
$42.2K0.0%
NORTHERN TRUST CORP
$37.9K+42.7%
XTX Topco Ltd
$35.8K+178.0%
Asset Advisory Group, Inc.
$35.7K0.0%
BostonPremier Wealth LLC
$16.9KNew
UBS Group AG
$15.9K-52.1%
LPL Financial LLC
$15.4K+1.6%
STATE STREET CORP
$14.1K0.0%
Virtu Financial LLC
$13.0KNew
Arkadios Wealth Advisors
$12.1K0.0%
TWO SIGMA INVESTMENTS, LP
$10.6K+33.2%
Sanctuary Advisors, LLC
$7.1KNew
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$7.1K-68.0%
R Squared Ltd
$6.7KNew
TWO SIGMA SECURITIES, LLC
$6.0KNew
SBI Securities Co., Ltd.
$5.8K+46.0%
CHELSEA COUNSEL CO
$2.8K0.0%
Quent Capital, LLC
$2.6K-0.8%
IFP Advisors, Inc
$2.5K-40.9%
See all 43 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2026
EDGAR

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

ROIC

Q3 2026
EDGAR

Debt/Equity

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/CTXR

Earnings Per Share

13fpro.ai/company/CTXR

Loading ratio trend…

CTXR key financials by period

Reported revenue, net income and operating margin by fiscal year, from Citius Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

Citius Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$90.0K$-33.6M—
FY 2021$90.0K$-23.1M—
FY 2020$90.0K$-17.5M—
FY 2019$90.0K$-15.6M—
FY 2018$75.0K$-12.5M—
FY 2017$50.0K$-10.4M—
Source: CTXR filings on SEC EDGAR →

About Citius Pharmaceuticals, Inc. (CTXR): stock profile, AI score and financials

Citius Pharmaceuticals, Inc. (CTXR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CTXR is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q3 2026), Citius Pharmaceuticals, Inc. reports quarterly revenue of $1.5M, net income of $-11.9M. Top institutional holders of CTXR by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, Miller Financial Services, based on the most recent SEC filings. CTXR trades on the Nasdaq exchange and files with the SEC under CIK 1506251. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTXR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Citius Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1506251 →